Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase II study.
Authors
Mingyue Cai
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;
Mingyue Cai , Xiaoyang Hong , Wensou Huang , Yongjian Guo , Wenbo Shi , Licong Liang , Jingwen Zhou , Liteng Lin , Ye Chen , Kangshun Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04599777
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 574)
DOI
10.1200/JCO.2023.41.4_suppl.574
Abstract #
574
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.
First Author: Xiang Nong
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC): A randomized, controlled, phase II clinical study.
First Author: Hui Zeng
Poster
2022 ASCO Annual Meeting
Efficacy and safety of low-dose apatinib in advanced hepatocellular carcinoma.
First Author: Lingbin Meng
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
First Author: Guoliang Shao